Enter your email to access this webinar
About This Webinar
First-in-class therapies have the potential to transform patient lives—especially where no effective options exist today. But with innovation comes uncertainty: scarce precedent, limited datasets, and high-risk decisions that can slow progress or stall promising programs.
In this webinar, Adam Petrich and Omri Matalon will explore the central challenge: Can AI give us an edge in first-in-class programs? We’ll examine why conventional AI often falls short in these settings, and how QuantHealth is addressing this challenge to close evidence gaps, de-risk decisions, and accelerate timelines in drug development.
Discover how leading clinical development teams are using QuantHealth’s solution to design high-impact protocols, reduce blind spots in go/no-go decisions, and surface powerful insights early—enabling smarter evaluation of clinical strategies in high-risk, high-reward programs.
Agenda
● The unique challenge of AI in first-in-class programs: Limited data and high-uncertainty decisions make applying AI in these settings especially difficult.
● Can AI give us an edge? Explore QuantHealth’s unique approach to overcoming the data-scarcity challenge in novel programs
● What success looks like: See how leading teams are using QuantHealth’s solution to advance first-in-class programs with stronger designs, clearer decisions, and faster timelines.
Meet the Speakers
Adam has extensive experience in all stages of oncology drug development (ranging from pre-IND to NDA/BLA), across a range of platforms (small molecules, mAb/ADC, immuno-oncology), spanning both solid tumors and hematologic malignancies. He has worked for and with many of today’s most innovative pharmaceutical companies, including AbbVie, Daiichi-Sankyo, AstraZeneca, and Roche/Genentech, and has extensive cross-functional and leadership experience, including clinical and commercial development, regulatory and medical affairs, business development, and licensing. He is trained as a hematologist and medical oncologist, and prior to joining the pharmaceutical industry, specialized in developmental therapeutics as a faculty member at the Feinberg School of Medicine and the Lurie Cancer Center, both at Northwestern University in Chicago.
Omri brings extensive expertise at the intersection of biomedicine and machine learning, with a career spanning molecular immunology, applied data science, and drug development across diverse therapeutic areas and modalities. He currently serves as Head of R&D at QuantHealth, where he leads multidisciplinary teams across clinical, data science, engineering, and business functions to advance data-driven drug development. Trained as a molecular immunologist, Omri earned his Ph.D. at Bar-Ilan University and has dedicated his career to applying data science to biomedical research, with a focus on driving innovation in drug discovery and development strategies.